Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABM-1310 Monotherapy and Combination in BRAF-Mutated Solid Tumors
NCT04190628Phase 1Terminated
- Sponsor
- ABM Therapeutics
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abm-1310 in solid tumor (advanced stage), primary central nervous system tumor and melanoma (6 arms), sponsored by ABM Therapeutics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose up to 6 months, Number of participants with treatment-related adverse events and 1 more. Started Jun 2020; status: terminated.
02
Drugs
abm-1310
03
Conditions
solid tumor (advanced stage)primary central nervous system tumormelanoma
Beyond the preview
Go deeper on NCT04190628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190628.